KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 112 filers reported holding KEROS THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $44,837,021 | -5.7% | 1,406,431 | +18.8% | 0.00% | 0.0% |
| Q2 2023 | $47,564,239 | +6.3% | 1,183,779 | +12.9% | 0.00% | 0.0% |
| Q1 2023 | $44,752,247 | -10.8% | 1,048,062 | +0.3% | 0.00% | 0.0% |
| Q4 2022 | $50,196,267 | +47.2% | 1,045,320 | +15.3% | 0.00% | 0.0% |
| Q3 2022 | $34,105,000 | +60.0% | 906,574 | +17.5% | 0.00% | 0.0% |
| Q2 2022 | $21,320,000 | -46.8% | 771,618 | +4.8% | 0.00% | 0.0% |
| Q1 2022 | $40,056,000 | -6.7% | 736,593 | +0.4% | 0.00% | 0.0% |
| Q4 2021 | $42,930,000 | +52.9% | 733,720 | +3.4% | 0.00% | 0.0% |
| Q3 2021 | $28,078,000 | -1.1% | 709,761 | +6.2% | 0.00% | 0.0% |
| Q2 2021 | $28,378,000 | -23.5% | 668,203 | +10.9% | 0.00% | 0.0% |
| Q1 2021 | $37,092,000 | -11.2% | 602,646 | +1.8% | 0.00% | 0.0% |
| Q4 2020 | $41,778,000 | +262.4% | 592,255 | +98.1% | 0.00% | – |
| Q3 2020 | $11,529,000 | -1.6% | 298,931 | -4.3% | 0.00% | – |
| Q2 2020 | $11,719,000 | – | 312,407 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 407,633 | $12,995,340 | 5.15% |
| Opaleye Management Inc. | 360,400 | $11,489,552 | 3.74% |
| Parkman Healthcare Partners LLC | 298,475 | $9,515,383 | 1.74% |
| BRAIDWELL LP | 1,357,309 | $43,271,011 | 1.37% |
| First Light Asset Management, LLC | 421,438 | $13,435,443 | 1.28% |
| Orbimed Advisors | 1,514,734 | $48,289,720 | 1.03% |
| Yiheng Capital Management, L.P. | 554,151 | $17,666,334 | 0.90% |
| Nantahala Capital Management | 328,781 | $10,481,538 | 0.90% |
| DAFNA Capital Management LLC | 65,961 | $2,102,837 | 0.65% |
| EDBI Pte Ltd | 10,105 | $322,147 | 0.35% |